CLEARPOINT NEURO INC (CLPT)
US18507C1036 - Common Stock
ClearPoint Neuro Reports Third Quarter 2024 Results
ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024
SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene...
ClearPoint Neuro Announces Early Repayment of $10 Million Note
ClearPoint Neuro clears all debt from balance sheet after early repayment of principal & interest on $10 million convertible note held by PTC Therapeutics...
CLPT Stock Earnings: ClearPoint Neuro Beats EPS, Beats Revenue for Q2 2024
CLPT stock results show that ClearPoint Neuro beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
CLPT Stock Earnings: ClearPoint Neuro Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips ClearPoint Neuro (NASDAQ:CLPT) just reported results for the second quarter of ...
ClearPoint Neuro Reports Second Quarter 2024 Results
ClearPoint Neuro reported Q2 2024 revenue of $7.9M, up 32% YoY, and raised full-year guidance to $30-33M #CLPT ...
The 3 Best Brain-Computer Interface Stocks to Buy Now
With the number of U.S. citizens aged 65 and above growing to 55.8 million, we could see brain-computer interface stocks accelerate.
ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024
SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene...
7 Growth Stocks That Could 5X in 5 Years
These top growth stocks across various sectors have the potential to deliver 5X returns in just five years.
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial
ClearPoint® Navigation System to be used for all enrolled patients in Aspen's ASPIRO Parkinson's cell therapy clinical trial ...
Parkinson's Disease Clinical Trial Uses Intraoperative MRI to Guide Precision Implantation of Patients' Own Autologous Replacement Neurons
/PRNewswire/ -- Aspen Neuroscience, Inc. announced today that it is utilizing the MRI-guided ClearPoint® Navigation System for all patients enrolled in the...
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System
Newly Launched ClearPoint Neuro technology - SmartFrame OR and Prism Laser will be on display at ASSFN in Nashville from June 1 - 4...
CLPT Stock Earnings: ClearPoint Neuro Beats EPS, Beats Revenue for Q1 2024
CLPT stock results show that ClearPoint Neuro beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
CLPT Stock Earnings: ClearPoint Neuro Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips ClearPoint Neuro (NASDAQ:CLPT) just reported results for the first quarter of 2...
7 Penny Stocks That Could Make You a Fortune (If You Dare)
These penny stocks offer robust operational opportunities amid wider economic and market concerns pushing weaker companies downward.
ClearPoint Neuro félicite son partenaire AviadoBio pour son premier patient traité dans le cadre de son essai clinique ASPIRE-FTD évaluant l’AVB-101 dans la démence fronto-temporale avec mutations du gène GRN
Les centres ASPIRE-FTD dans l’UE et aux États-Unis utiliseront la navigation ClearPoint® avec la canule SmartFlow® pour l’administration de thérapie...
ClearPoint Neuro beglückwünscht seinem Partner AviadoBio zur Behandlung des ersten Patienten in der klinischen Studie ASPIRE-FTD, in der AVB-101 für frontotemporale Demenz mit GRN-Mutationen evaluiert wird
Prüfzentren für ASPIRE-FTD in der EU und den USA verwenden ClearPoint® Navigation zusammen mit der SmartFlow®-Kanüle für die intrathalamische Gentherapie...
ClearPoint Neuro si congratula con il proprio partner AviadoBio per il primo paziente trattato nello studio clinico ASPIRE-FTD, che valuta la terapia genica sperimentale AVB-101 per la demenza frontotemporale con mutazioni GRN
I siti ASPIRE-FTD nell’UE e negli Stati Uniti utilizzeranno la navigazione ClearPoint® insieme alla cannula SmartFlow® per la somministrazione della...
ClearPoint Neuro felicita a su socio AviadoBio por el primer paciente tratado en su ensayo clínico ASPIRE-FTD que evalúa AVB-101 en personas con demencia frontotemporal con mutaciones en el gen GRN
Los centros ASPIRE-FTD de la UE y EE. UU. ...
ClearPoint Neuro feliciteert partner AviadoBio met de behandeling van de eerste patiënt in klinisch onderzoek ASPIRE-FTD, waarin AVB-101 wordt geëvalueerd voor frontotemporale dementie met GRN-mutaties
De onderzoekscentra van ASPIRE-FTD in de EU en de VS zullen gebruikmaken van ClearPoint® Navigation in combinatie met de SmartFlow® Cannula voor de...
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
ClearPoint Neuro platform and SmartFlow Cannula to be used by all centers in AviadoBio's ASPIRE-FTD gene therapy trial treating frontotemporal dementia...
ClearPoint Neuro Becomes Oversold (CLPT)
The 3 Most Promising MedTech Stocks to Invest In Now
MedTech stocks are often overlooked despite the inherent healthcare growth trajectory and industry-wide innovative spirit.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)
/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating ClearPoint Neuro, Inc. (NASDAQ: CLPT) on behalf of the company's shareholders. The...
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
ClearPoint Neuro's partner's completed BLA Submission for Upstaza™ would be first disease-modifying treatment for AADC Deficiency in the US....
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results
ClearPoint Neuro reports 32% growth in fourth quarter as compared to fourth quarter of 2022. Biologics revenue increased 49% YOY. ...
The Top 7 Under-$15 Stocks to Buy in March 2024
These under-$15 stocks to buy are one of the few deals remaining in today's economic environment. Don't miss out.
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024
SOLANA BEACH, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene...
ClearPoint Neuro prices offering of about 2.3M shares (NASDAQ:CLPT)
ClearPoint Neuro announces pricing of its underwritten public offering of 2,307,694 shares of common stock at $6.50 per share, with an option for additional...
ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock
SOLANA BEACH, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene...
ClearPoint Neuro stock falls 10% after it announces an equity raise (NASDAQ:CLPT)
ClearPoint Neuro (CLPT) announces a public offering of common stock and grants underwriters an option to purchase additional shares.
ClearPoint Neuro Launches Proposed Public Offering of Common Stock
SOLANA BEACH, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene...